Search results | osteoporosis

Reports

Osteoporosis Partnering

The Osteoporosis Partnering report provides understanding and access to the osteoporosis partnering deals and agreements entered into by the worlds leading healthcare companies.

Insights

NPS Pharmaceuticals – developing and partnering for rare diseases

NPS Pharmaceuticals is a global pharmaceutical company treating rare diseases specifically focusing upon gastrointestinal and endocrine disorders.

Warner Chilcott

Warner Chilcott is a top pharmaceutical company based in Dublin, Ireland

Abbott Laboratories

Abbott Laboratories is a top pharmaceutical company based in Illinois, USA

Healthcare M&A trends of 2013 so far

The healthcare sector in 2013 continues to adjust to a new environment of sluggish economic growth, budget constraints, reimbursement challenges, higher regulatory hurdles, and the uncertainties surrounding healthcare reform. Just recently, the European Parliament recently approved, by an overwhelming margin, a tightening up of CE-mark pre-market authorizations and post-mark surveillance of medical devices

UCB Pharma; Combining biology and chemistry to crack the CNS market

UCB Pharma is a global biopharma company developing treatments for diseases of the immune and central nervous system.

Servier: Investing in and leading research like no other

Servier is a European research based pharmaceutical company focusing on the areas of oncology, cardiovascular and Central Nervous System diseases.

Dendreon: Company profile

Dendreon, a top big biotech company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Ipsen: Company profile

Ipsen, a top big biotech company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years.

Warner Chilcott: Company Profile

Warner Chilcott, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Partnering with Novartis: Partners for innovation and success

Novartis is a top pharma company active in partnering, licensing and M&A in pharmaceuticals

Events

Sorry, your search returned no results.


Deals

Galapagos achieves milestones in osteoporosis alliance

Galapagos NV announced today that it has reached milestones in its osteoporosis alliance with Eli Lilly & Co., resulting in payments of €2.9m from Lilly. Read Galapagos/Lilly article here (link no longer available)

Amgen to collaborate with GlaxoSmithKline to commercialize Denosumab in Europe for postmenopausal osteoporosis

Financial terms of the partnership include an initial payment and near-term commercial milestones to Amgen totaling $120 million, and ongoing royalties. In Europe, Amgen and GlaxoSmithKline will share profits after accounting for expenses associated with the partnership. In emerging markets, GlaxoSmithKline will be responsible for all commercialization expenses and purchase denosumab from Amgen to meet more »

EffRx in expansion of licensing deal with Nycomed for effervescent osteoporosis drug EX101

EffRx will receive from Nycomed additional upfront and milestone payments of up to US$15m.

EffRx signs licensing deal with Nycomed for effervescent osteoporosis drug EX101

EffRx will receive from Nycomed upfront and milestone payments up to $59m.

Eli Lilly and Zosano partner for PTH using microneedle patch system

Zosano Pharma and Eli Lilly have entered into an exclusive agreement to develop ZP-PTH

Radius Health files for $86 million IPO financing

Radius Health, a biotech developing treatments to restore bone loss from osteoporosis, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering financing.

Amgen big pharma deals Astellas in Amgen Astellas Biopharma joint venture

Amgen has entered into big pharma deals with Astellas in creating a joint venture names Amgen Astellas Biopharma.

Amgen proposes biotech business development with Astellas

Amgen, a top big pharma and big biotech company, entered into a long-term collaboration proposing a biotech business development with Astellas and will form a joint venture with the Japanese drugmaker to provide new medicines in Japan.

Amgen and UCB terminates romosozumab development agreement

Amgen and UCB terminates efforts to develop romosozumab for fracture healing, although trials in post-menopausal osteoporosis will continue.

Merck & Regenstrief Institute sign pharma partners deal for evidence-based care

A pharma partners agreement was singed between Merck, a big pharma company and The Regenstrief Institute to collaborate on a range of projects that will use clinical data to inform personalized delivery of health care